

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
21 July 2022 (21.07.2022)



(10) International Publication Number
WO 2022/155614 A1

(51) International Patent Classification:

<i>C07J 63/00</i> (2006.01)	<i>A61P 19/02</i> (2006.01)
<i>C07J 71/00</i> (2006.01)	<i>A61P 21/06</i> (2006.01)
<i>A61P 1/18</i> (2006.01)	<i>A61P 25/00</i> (2006.01)
<i>A61P 3/00</i> (2006.01)	<i>A61P 25/28</i> (2006.01)
<i>A61P 3/10</i> (2006.01)	<i>A61P 27/02</i> (2006.01)
<i>A61P 7/06</i> (2006.01)	<i>A61P 29/00</i> (2006.01)
<i>A61P 9/00</i> (2006.01)	<i>A61P 31/04</i> (2006.01)
<i>A61P 9/10</i> (2006.01)	<i>A61P 31/16</i> (2006.01)
<i>A61P 11/00</i> (2006.01)	<i>A61P 35/00</i> (2006.01)
<i>A61P 11/06</i> (2006.01)	<i>A61P 37/06</i> (2006.01)
<i>A61P 13/12</i> (2006.01)	<i>A61K 31/575</i> (2006.01)
<i>A61P 17/00</i> (2006.01)	<i>A61K 31/58</i> (2006.01)

(21) International Application Number:

PCT/US2022/012831

(22) International Filing Date:

18 January 2022 (18.01.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/199,694 18 January 2021 (18.01.2021) US

(71) Applicant: **REATA PHARMACEUTICALS, INC.**
[US/US]; 2801 Gateway Drive, Suite 150, Irving, TX 75063 (US).

(72) Inventors: **JIANG, Xin**; 902 Mill Trail, Coppell, TX 75019 (US). **DO, Ha**; c/o Reata Pharmaceuticals, Inc., 2801 Gateway Drive, Suite 150, Irving, TX 75063 (US). **SUN, Haizhou**; c/o Reata Pharmaceuticals, Inc., 2801 Gateway Drive, Suite 150, Irving, TX 75063 (US). **VISNICK, Mc-lean**; 330 East Las Colinas Blvd., Unit 428, Irving, TX 75039 (US). **KRAL, Robert, M., Jr.**; 2405 Brittany Lane, Grapevine, TX 76051 (US).

(74) Agent: **VOGES, Mark, H.**; Parker Highlander PLLC, 1120 S. Capital of Texas Highway, Bldg. One, Suite 200, Austin, TX 78746 (US).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM,


AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: SYNTHETIC URSOLIC ACID DERIVATIVES AND METHODS OF USE THEREOF



(I-A)

(57) Abstract: Disclosed herein are compounds of Formula (I-A), wherein the variables are defined herein. Also provided are pharmaceutical compositions thereof. In some aspects, the compounds and compositions provided herein may be used as antioxidant inflammation modulators. In some aspects, the present disclosure provides methods wherein the compounds and composition described herein are used for the treatment of diseases and disorders associated with inflammation and cancer.

WO 2022/155614 A1